Alcon Laboratories, Inc.

Novartis Ag

Alcon Pharmaceuticals Ltd.

Alcon, Inc.

Alcon Research, Ltd.

Rajni Jani

Yusuf Ali

Masood A Chowhan

Bhagwati P Kabra

Wesley Wehsin Han

G Michael Wall

Onkar N Singh

Robert G Harris

Thomas R Dean

Louis DeSantis, Jr

Steven Howard Gerson

John C Lang

Ole J Lorenzetti

Paul J Missel

George R McCarty

Owen Gan

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.

Olopatadine formulations for topical nasal administration

Aqueous pharmaceutical compositions containing a synergistic combination of a quinolone and a polystyrene sulfonic acid polymer are described, wherein the compositions are clear solutions which are comfortable and have sustained release. Methods for use of the compositions are also disclosed. This type of formulation is particularly useful with ciprofloxacin-type quinolones by greatly increasing the solubility of these quinolones, making it feasible to have aqueous solutions containing such quinolones at or near physiological pH.

Antibacterial compositions

Disclosed are nonstinging, sustained release ophthalmic formulations to control intraocular pressure in antiglaucoma therapy comprising a basic active, a cation exchange resin, and, inter alia, an acidic, mucomimetic polymer. Also disclosed are methods of treatment comprising administering such formulations topically to the eye when indicated for control and lowering of intraocular pressure.

Sustained release comfort formulation for glaucoma therapy

The present invention is directed to topical ophthalmic formulations of carbonic anhydrase inhibitors and polyethoxylated derivatives of castor oil. Methods for using the formulations for treating and controlling glaucoma and ocular hypertension are also disclosed.

Topical ophthalmic carbonic anhydrase inhibitor formulations

Compositions for controlling glaucoma and ocular hypertension are disclosed.

Compositions for treatment of glaucoma

Improved ophthalmic irrigating solutions are described. The solutions include one or more drugs for controlling intraocular pressure, an antioxidant/free radical scavenger, electrolytes, a cellular energy source, bicarbonate, and a buffer. Methods of using the solutions in connection with ophthalmic surgical procedures are also described.

Intraocular irrigating solution containing agent for controlling IOP

Ophthalmic compositions comprising combinations of gelling polysaccharides and finely-divided drug carrier substrates which become relatively more viscous on contact with the eye are disclosed. These ophthalmic compositions are both comfortable and long-lasting Ophthalmic compositions further comprising a pharmaceutically active drug are also disclosed, as are methods of use.

Use of combinations gelling polysaccharides and finely divided drug

Ophthalmic pharmaceutical compositions useful in controlling elevated intraocular pressure associated with glaucoma and ocular hypertension are described. The compositions comprise a combination of a beta-blocker to reduce the production of aqueous humor and carbachol to enhance the outflow of aqueous humor. A method of controlling elevated intraocular pressure with those compositions is also described.

Anti-glaucoma compositions

Disclosed are nonstinging, sustained release ophthalmic formulations. The formulations comprise a cationic drug, an acidic mucomimetic polymer and a polystyrene sulfonic acid polymer. In particular, formulations for the control of intraocular pressure and glaucoma are disclosed. Methods for use of the formulations are also disclosed.

Growing community of inventors

Fort Worth, TX, United States of America

Rajni Jani